The European Medicines Agency (EMA) has finalized its reflection paper on the frailty of senior clinical trial participants after receiving feedback from the U.S. FDA. The purpose of the document is to encourage sponsors to assess the baseline frailty characteristics of trial subjects; notably, a frailty assessment could take 10-15 minutes and add to the burden on subjects and sites. (Regulatory Focus)